SG11202011927TA - Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease - Google Patents

Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease

Info

Publication number
SG11202011927TA
SG11202011927TA SG11202011927TA SG11202011927TA SG11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA
Authority
SG
Singapore
Prior art keywords
prevention
treatment
pharmaceutical composition
stem cells
mesenchymal stem
Prior art date
Application number
SG11202011927TA
Inventor
yun sun Yang
Wonil Oh
Soo Jin Choi
Jihye Kwak
Dong Hyon Kim
Hoon Lim
Original Assignee
Medipost Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medipost Co Ltd filed Critical Medipost Co Ltd
Publication of SG11202011927TA publication Critical patent/SG11202011927TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG11202011927TA 2018-06-05 2019-06-05 Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease SG11202011927TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862680748P 2018-06-05 2018-06-05
PCT/KR2019/006817 WO2019235854A1 (en) 2018-06-05 2019-06-05 Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease

Publications (1)

Publication Number Publication Date
SG11202011927TA true SG11202011927TA (en) 2020-12-30

Family

ID=68769796

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202012124PA SG11202012124PA (en) 2018-06-05 2019-06-05 Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease
SG11202011927TA SG11202011927TA (en) 2018-06-05 2019-06-05 Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11202012124PA SG11202012124PA (en) 2018-06-05 2019-06-05 Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease

Country Status (9)

Country Link
US (2) US20210228637A1 (en)
EP (2) EP3811951A4 (en)
JP (2) JP7343091B2 (en)
KR (2) KR20210008101A (en)
CN (2) CN112261943A (en)
AU (2) AU2019283518A1 (en)
CA (2) CA3100466A1 (en)
SG (2) SG11202012124PA (en)
WO (2) WO2019235853A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220152137A (en) 2021-05-07 2022-11-15 의료법인 성광의료재단 A mesenchymal stem cell with enhanced osteogenic differentiation capacity and an use thereof
CN113616675A (en) * 2021-08-23 2021-11-09 上海太安堂生物医学有限公司 Composition containing mesenchymal stem cells and application thereof in treating degenerative arthritis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015802A1 (en) * 2001-08-14 2003-02-27 Medipost, Co., Ltd. Composition for treatment of articular cartilage damage
AU2004242091C1 (en) * 2003-05-07 2009-12-24 La Jolla Institute For Molecular Medicine Administration of hyaluronic acid to enhance the function of transplanted stem cells
EP2298863B1 (en) 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP5048323B2 (en) 2004-03-31 2012-10-17 株式会社ツーセル Therapeutic agent and treatment method for damaged tissue
US8444968B2 (en) * 2005-12-07 2013-05-21 Isto Technologies, Inc. Cartilage repair methods
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
NZ612888A (en) * 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
EP2164505B1 (en) * 2007-05-28 2014-09-17 Monash University Treatment of chronic lung disease
EP2257289B1 (en) * 2008-02-15 2018-09-19 Bone Therapeutics Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
CN103263440A (en) * 2013-02-08 2013-08-28 周胜利 Method for extracting and preparing homology mesenchymal stem cell injection from placenta and umbilical cord
US20160184364A1 (en) * 2013-08-14 2016-06-30 Stempeutics Research Pvt. Ltd. Management of osteoarthritis using pooled allogeneic mesenchymal stem cells
JP6173157B2 (en) 2013-10-02 2017-08-02 日本製薬株式会社 IL-17 production inhibiting composition
US20170166869A1 (en) * 2014-02-04 2017-06-15 Jose Javier Lopez GONZALEZ Biologically optimized adult mesenchymal stem cells
GB201410504D0 (en) * 2014-06-12 2014-07-30 Cell Therapy Ltd Immuno-modulaltory progenitor (IMP) cell
BR112016030758B8 (en) 2014-06-30 2022-10-25 Tigenix S A U USE OF MULTIPOTENT STROME CELLS DERIVED FROM MESENCHYMAL ADIPOSE TISSUE
KR101779763B1 (en) * 2015-03-04 2017-09-19 메디포스트(주) Pharmaceutical composition for the prevention or treatment of a lung disease comprising mesenchymal stem cells having improved proliferation and differentiation capacity
JP6811724B2 (en) 2015-04-24 2021-01-13 ティジェニクス エス．エー．ユー． Biomarkers to determine clinical response to cell therapy
CN104840486A (en) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 Composition, application thereof and preparation
HUP1500218A2 (en) * 2015-05-08 2016-11-28 Deltabio 2000 Kft Method and composition for treatment of orthopedic diseases articular cortilage injuries and particularly to dysphoria
EP3097922A1 (en) 2015-05-28 2016-11-30 Denis Barritault Composition for the treatment of tissue lesions
AU2017225902B2 (en) 2016-02-29 2022-12-22 Magellan Stem Cells Pty Ltd Methods of treatment
CN105796600B (en) * 2016-04-28 2020-02-28 博雅干细胞科技有限公司 Methods and compositions for treating osteoarthritis using stem cells
US20180021380A1 (en) * 2016-07-21 2018-01-25 Sungkwang Medical Foundation Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same
JP7179723B2 (en) * 2016-10-24 2022-11-29 ユナイテッド セラピューティクス コーポレイション Enhancing the Immunomodulatory Properties of MSCs by Treprostinil
MX2019005127A (en) * 2016-11-03 2019-09-26 Exostem Biotec Ltd Mesenchymal stem cells populations, their products, and use thereof.
CN111518758A (en) * 2020-04-30 2020-08-11 深圳市合一康生物科技股份有限公司 Umbilical cord mesenchymal stem cells for treating lung diseases and preparation method thereof
CN113018317A (en) * 2021-02-03 2021-06-25 上海兰天生物医药科技有限公司 Application of mesenchymal stem cells and sodium hyaluronate in treatment of arthritis

Also Published As

Publication number Publication date
KR20210008101A (en) 2021-01-20
SG11202012124PA (en) 2021-01-28
US20210228636A1 (en) 2021-07-29
CA3100471A1 (en) 2019-12-12
CA3100466A1 (en) 2019-12-12
KR20210008873A (en) 2021-01-25
US20210228637A1 (en) 2021-07-29
JP7343091B2 (en) 2023-09-12
JP2021526135A (en) 2021-09-30
WO2019235854A1 (en) 2019-12-12
CN112261944A (en) 2021-01-22
WO2019235853A1 (en) 2019-12-12
EP3804736A1 (en) 2021-04-14
CN112261943A (en) 2021-01-22
AU2019283518A1 (en) 2021-01-14
AU2019283517A1 (en) 2021-01-21
EP3811951A4 (en) 2022-07-13
EP3811951A1 (en) 2021-04-28
JP7480454B2 (en) 2024-05-10
JP2021526137A (en) 2021-09-30
EP3804736A4 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
IL288375A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
EP3586853A4 (en) Pharmaceutical composition comprising inflammation-stimulated mesenchymal stem cell for prevention or treatment of immune disease or inflammatory disease
IL279397A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
ZA202002166B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL286677A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201907558D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201911868D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL286688A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL257336B (en) Compounds and pharmaceutical compositions for prevention or treatment of parasitic diseases
MX2021003643A (en) Terpinoid derivatives and uses thereof.
SG11202011927TA (en) Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
EP3643302C0 (en) Composition containing sesquiterpene derivative as active ingredient for prevention or treatment of muscle diseases
SG11202106163RA (en) Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient
EP3603656A4 (en) Pharmaceutical composition for prevention or treatment of gynecological diseases containing extract of sarcodon imbricatus as active ingredient
IL285751A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL286685A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3795170C0 (en) Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal diseases
HUE053866T2 (en) Pharmaceutical composition for the treatment of constipation
EP3903803A4 (en) Pharmaceutical composition comprising pibf protein as active ingredient for prevention or treatment of inflammatory disease
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
GB201817344D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201817343D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
GB201809836D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases